Mirati's Adagrasib Shows Promising Efficacy In KRAS Mutated Colorectal Cancer

Mirati Therapeutics Inc MRTX announced results from the KRYSTAL-1 Phase 1/2 study of adagrasib with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation.
The data will be presented at the European Society for Medical Oncology (ESMO) Congress 2022.
In this analysis, 44 patients received adagrasib monotherapy, and 32 received the combination of adagrasib + cetuximab, with a follow-up of 20.1 months and 17.5 months, respectively.
Related: Mirati Therapeutics Posts Adagrasib Data In Lung Cancer Patients With CNS Metastases.
In the adagrasib monotherapy cohort, the investigator-assessed confirmed objective response rate (ORR) was 19%, and the disease control rate (DCR) was 86% (37/43). The median duration of response was 4.3 months, and the median progression-free survival (PFS) was 5.6 months.
In the adagrasib combo regime, ORR was 46%, and the DCR was 100% (28/28). The median DOR was 7.6 months, and the median PFS was 6.9 months.
Adagrasib was well-tolerated as a monotherapy and in combination with cetuximab. Most observed treatment-related adverse events (TRAEs) were mild or moderate; no grade 5 TRAEs were observed.
Price Action: MRTX shares are down 1.62% at $79.00 during the premarket session on the last check Thursday.